Tvardi Therapeutics, Inc. (TVRD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 2.57M | 0 | 0 | 0 | 2.13M | 3M | 4.87M |
| Revenue Growth % | - | - | - | 20.33% | -100% | -100% | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 47K | 0 | 0 | 0 | 5K | 620K | 690K | 1.62M |
| COGS % of Revenue | - | - | - | - | - | - | - | 29.04% | 22.97% | 33.23% |
| Gross Profit | 0 | 0 | -47K | 2.57M | 0 | 0 | -5K | 1.51M | 2.31M | 3.25M |
| Gross Margin % | - | - | - | 100% | - | - | - | 70.96% | 77.03% | 66.77% |
| Gross Profit Growth % | - | - | -840% | 69.57% | -100% | -100% | - | - | - | - |
| Operating Expenses | 7.59M | 5.94M | 8.82M | 4.96M | 10.8M | 5.68M | 7.18M | 31.18M | 34.92M | 32.15M |
| OpEx % of Revenue | - | - | - | 192.88% | - | - | - | 1460.47% | 1162.48% | 660.65% |
| Selling, General & Admin | 2.1M | 2.33M | 3.06M | 4.64M | 2.2M | 881K | 645K | 6.79M | 6.55M | 6.72M |
| SG&A % of Revenue | - | - | - | 180.46% | - | - | - | 317.85% | 218.01% | 138.18% |
| Research & Development | 5.49M | 3.6M | 5.81M | 319K | 8.6M | 4.79M | 6.53M | 21.96M | 28.37M | 25.42M |
| R&D % of Revenue | - | - | - | 12.42% | - | - | - | 1028.76% | 944.47% | 522.46% |
| Other Operating Expenses | 0 | 0 | -47K | 0 | 0 | 0 | 0 | 1000K | 0 | 0 |
| Operating Income | -7.59M | -5.94M | -8.87M | -2.39M | -10.8M | -5.68M | -7.18M | -29.67M | -32.61M | -28.9M |
| Operating Margin % | - | - | - | -92.88% | - | - | - | -1389.51% | -1085.45% | -593.88% |
| Operating Income Growth % | 29.76% | -4.62% | -23.51% | 91.96% | 66.87% | 80.36% | - | - | - | - |
| EBITDA | -7.56M | -5.91M | -8.82M | -2.36M | -10.78M | -5.65M | -7.18M | -29.62M | -32.52M | -28.38M |
| EBITDA Margin % | - | - | - | -91.94% | - | - | - | -1387.54% | -1082.72% | -583.17% |
| EBITDA Growth % | 29.83% | -4.64% | -22.94% | 92.03% | 66.86% | 80.08% | - | - | - | - |
| D&A (Non-Cash Add-back) | 24K | 24K | 47K | 24K | 24K | 24K | 5K | 42K | 82K | 521K |
| EBIT | -7.28M | -5.53M | 4.17M | -2.04M | -10.09M | -3.55M | -6.97M | -28.71M | -31.73M | -28.03M |
| Net Interest Income | 312K | 411K | 377K | -2.87M | -2.2M | -1.19M | -1.7M | -1.98M | 313K | 866K |
| Interest Income | 312K | 411K | 377K | 0 | 421K | 766K | 206K | 0 | 313K | 866K |
| Interest Expense | 0 | 0 | 0 | 2.87M | 2.62M | 1.96M | 1.91M | 1.98M | 0 | 0 |
| Other Income/Expense | 312K | 411K | 13.04M | -2.52M | -1.91M | 163K | 206K | -1.03M | 270K | 866K |
| Pretax Income | -7.28M | -5.53M | 4.17M | -4.91M | -12.71M | -5.51M | -6.97M | -30.7M | -32.34M | -28.03M |
| Pretax Margin % | - | - | - | -190.97% | - | - | - | -1437.75% | -1076.46% | -576.08% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.28M | -5.53M | 4.17M | -4.91M | -12.71M | -5.51M | -6.97M | -30.7M | -32.34M | -28.03M |
| Net Margin % | - | - | - | -190.97% | - | - | - | -1437.75% | -1076.46% | -576.08% |
| Net Income Growth % | 42.75% | -0.25% | 159.74% | 84.02% | 60.7% | 80.33% | - | - | - | - |
| Net Income (Continuing) | -7.28M | -5.53M | 4.17M | -4.91M | -12.71M | -5.51M | -6.97M | -30.7M | -32.34M | -28.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.78 | -0.59 | -1.00 | -0.52 | -5.04 | -8.19 | -13.17 | -3.28 | -0.46 | -18.61 |
| EPS Growth % | 84.52% | 92.8% | 92.41% | 84.15% | -995.65% | 55.99% | - | - | - | - |
| EPS (Basic) | -0.78 | -0.59 | 0.51 | -0.52 | -5.04 | -8.19 | -13.17 | -3.28 | -0.46 | -18.61 |
| Diluted Shares Outstanding | 9.38M | 9.38M | 8.46M | 9.36M | 1.52M | 1.52M | 1.52M | 9.36M | 9.36M | 1.51M |
| Basic Shares Outstanding | 9.33M | 9.38M | 8.25M | 9.36M | 1.52M | 1.52M | 1.52M | 9.36M | 9.36M | 1.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |